AUROPHARMA

🌍 Global Business Developments

📊 Latest Results & Financials The company recently announced Q3 FY26 results with: Net profit growth year-on-year driven by strong sales in Europe and the US markets Revenue growth supported by generics and formulations business Earlier quarter also showed steady revenue and EBITDA growth with slight margin improvement. 🏭 Regulatory & Compliance Update Aurobindo Pharma received 11 observations from the USFDA after inspection of one of its manufacturing facilities. The observations were procedural in nature and the company indicated no major financial impact, but such inspections keep the stock in focus. 🏢 Acquisitions & Expansion The company is acquiring the non-oncology prescription business of Khandelwal Laboratories (multiple brands and pipeline products) to strengthen its India formulations segment. Increasing stake in overseas ventures and joint ventures to expand global presence. Incorporated a new step-down subsidiary in the Philippines as part of international expansion. Also investing in renewable energy and other strategic initiatives through subsidiaries. 🌍 Global Business Developments Strong focus on US and European generics markets, which remain key revenue drivers. Expanding specialty and complex generics portfolio. Ongoing efforts to diversify manufacturing footprint and product mix. 📉 Stock & Market Activity Stock has seen volatility recently due to: Regulatory news (USFDA inspections) Profit-booking after earlier rally At times the stock witnessed sharp volume spikes and sector-led rallies when pharma stocks performed strongly.